Vaccine profile of 4CMenB: a four-componentNeisseria meningitidisserogroup B vaccine

Genome-Based Bacterial Vaccines: Current State and Future Outlook

(2013) Alexandra Schubert-Unkmeir et al.   BIODRUGS

Comparison of posterior pharyngeal wall and nasopharyngeal swabbing as a means of detecting the carriage of Neisseria meningitidis in adolescents

(2013) S. Esposito et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Immunisation against meningococcus B

(2013) Adam Finn et al.   LANCET

Immunisation against meningococcus B

(2013) Jane Blewitt   LANCET

Immunisation against meningococcus B

(2013) Stanley A Plotkin   LANCET

Immunisation against meningococcus B

(2013) Steven Black   LANCET

Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials

(2013) Timo Vesikari et al.   LANCET

Novel assessment of a novel meningitis B vaccine

(2013) Christopher J Gill   LANCET INFECTIOUS DISEASES

Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment

(2013) Ulrich Vogel et al.   LANCET INFECTIOUS DISEASES

Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses

(2013) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Multi-country Evaluation of Neisseria meningitidis Serogroup B Factor H–Binding Proteins and Implications for Vaccine Coverage in Different Age Groups

(2013) Susan K. Hoiseth et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

(2013) Gail L. Rodgers et al.   VACCINE

Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact

(2013) Hannah Christensen et al.   VACCINE

Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine

(2013) Ouli Xie et al.   VACCINE

Cost-effectiveness of vaccination against meningococcal B among Dutch infants

(2013) Koen B. Pouwels et al.   Human Vaccines & Immunotherapeutics

Use of the 13-valent pneumococcal conjugate vaccine in infants and young children

(2012) Nicola Principi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules

(2012) Nicoletta Gossger et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study

(2012) María Elena Santolaya et al.   LANCET

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

(2012) Eva Hong et al.   VACCINE

Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers

(2011) C. Jackson et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Carriage ofNeisseria meningitidisin Europe: a review of studies undertaken in the region

(2011) Montse Soriano-Gabarró et al.   Expert Review of Anti-Infective Therapy

Differences in vaccinations in European Union

(2011) Susanna Esposito et al.   Human vaccines & immunotherapeutics

Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates

(2010) Alan Kimura et al.   Clinical and Vaccine Immunology

Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy

(2010) Jamie Findlow et al.   CLINICAL INFECTIOUS DISEASES

Review of Meningococcal Group B Vaccines

(2010) Dan M. Granoff   CLINICAL INFECTIOUS DISEASES

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

(2010) Karen Edmond et al.   LANCET INFECTIOUS DISEASES

Serogroup B meningococcal vaccines—an unfinished story

(2010) Manish Sadarangani et al.   LANCET INFECTIOUS DISEASES

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines

(2010) J. Donnelly et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine

(2009) Nicholas Kitchin et al.   VACCINE

Meningococcal carriage and disease—Population biology and evolution

(2009) Dominique A. Caugant et al.   VACCINE

Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years

(2008) Y. Galloway et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY